Cidara Therapeutics, Inc. (CDTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CDTX
- Company Cidara Therapeutics, Inc.
- Price $218.27
- Changes Percentage 0.26
- Change 0.56
- Day Low $217.41
- Day High $218.53
- Year High $218.85
- Year Low $14.33
- Market Cap $5,531,869,515
- Price Avg 50 EMA (D) $95.6
- Price Avg 200 EMA (D) $50.04
- Exchange NASDAQ
- Volume 3,358,636
- Average Volume 1,128,660
- Open $217.62
- Previous Close $217.71
- EPS -11.21
- PE -19.46
- Earnings Announcement 2025-11-06 21:00:00
- Shares Outstanding $25,358,100
Company brief: CIDARA THERAPEUTICS, INC. (CDTX )
- Healthcare
- Biotechnology
- Dr. Jeffrey L. Stein Ph.D.
- https://www.cidara.com
- US
- N/A
- 04-15-2015
- US1717571079
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
CDTX Corporation News
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
reuters.com -- Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' experimental flu drug....